Navegar por autor "Anido Herranz, Urbano"

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

2012- Barbazán, Jorge; Barbazán García, Jorge; Vieito Villar, María; Abalo Piñeiro, Alicia; Alonso Alconada, Lorena; [et al.]

Adenocarcinoma de ciego en paciente con situs inversus totalis.

2011- Abal Arca, José; Anido Herranz, Urbano; González Quintela, Arturo; Pazos González, Gerardo

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples

2012- Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; Firvida Perez, Jose Luis; León Mateos, Luis Ángel; [et al.]

Bone Turnover Markers and Potential Correlation with Outcomes in Patients with Genitourinary Cancer (Prostate) and Bone Metastasis (Results of Tugamo Study)

2012- Anido Herranz, Urbano; Gómez Caamaño, Antonio

Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC)

2015- Anido Herranz, Urbano; Fernández Nuñez, Natalia; Areses Manrique, María Carmen; Vázquez Estévez, Sergio; Covela Rúa, Marta [et al.]

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

2019- Anido Herranz, Urbano; Fernández Nuñez, Natalia; Afonso-Afonso, J.; Santome-Couto, L.; Medina-Colmenero, A.; [et al.]

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

2013- Afonso Afonso, Francisco Javier; Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; León Mateos, Luis Ángel; [et al.]

DESCRIPTION OF A SUBPOPULATION OF RENAL PATIENTS WITH LONG-TERM PROGRESSION FREE SURVIVAL (PFS) WITH SUNITINIB: A SOG_GU EXPERIENCE

2012- Afonso Afonso, Francisco Javier; Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor

2015- Afonso Afonso, Francisco Javier; Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; Lazaro Quintela, Martín; [et al.]

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment

2014- Anido Herranz, Urbano; Vieito Villar, María; Abalo Piñeiro, Alicia; Muinelo Romay , Laura; Alonso Nocelo, Marta; [et al.]

Evaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

2020- ABOU JOKH CASAS, ESTEPHANY; Pubul Nuñez, Virginia; Anido Herranz, Urbano; Mallón Araujo, María del Carmen; Del Pombo Pasín, Maria Carmen; [et al.]

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

2020- Puente, J.; Anido Herranz, Urbano; Climent, M.; Gonzalez-Billalabeitia, E.; Lainez, N.; [et al.]

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

2022- Durán, I.; Castellano, D.; Puente, J.; Martín-Couce, L.; Bello, E.; [et al.]

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor

2012- Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; Firvida Perez, Jose Luis; León Mateos, Luis Ángel; [et al.]

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

2020- León Mateos, Luis Ángel; Abal Posada, Miguel; Casas, H.; Anido Herranz, Urbano; Rapado-Gonzalez, O.; [et al.]

High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

2014- Cameselle Teijeiro, Jose Manuel; Cubiella Fernández, Joaquín; Brea Fernández, Alejandro; Anido Herranz, Urbano; Carracedo Álvarez, Ángel; [et al.]

High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion.

2011- Anido Herranz, Urbano; Barbazán García, Jorge; Alonso Alconada, Lorena; Muinelo Romay , Laura; Alonso Nocelo, Marta; [et al.]

Identification of protein expression signatures in clear renal cell carcinoma histological type

2012- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Anido Herranz, Urbano

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study

2011- Anido Herranz, Urbano; Firvida Perez, Jose Luis; Lazaro Quintela, Martín; Calvo Crespo, Patricia; Vázquez Estévez, Sergio; [et al.]

Long-term progression-free survival (PFS) in patients under sunitinib treatment: A SOG-GU experience

2012- Afonso Afonso, Francisco Javier; Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; León Mateos, Luis Ángel; [et al.]

Repositorio digital RUNA

Navegar por autor "Anido Herranz, Urbano"

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer ﻿

Adenocarcinoma de ciego en paciente con situs inversus totalis. ﻿

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples ﻿

Bone Turnover Markers and Potential Correlation with Outcomes in Patients with Genitourinary Cancer (Prostate) and Bone Metastasis (Results of Tugamo Study) ﻿

Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC) ﻿

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer ﻿

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor ﻿

DESCRIPTION OF A SUBPOPULATION OF RENAL PATIENTS WITH LONG-TERM PROGRESSION FREE SURVIVAL (PFS) WITH SUNITINIB: A SOG_GU EXPERIENCE ﻿

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor ﻿

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment ﻿

Evaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors ﻿

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE ﻿

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning ﻿

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor ﻿

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients ﻿

High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families ﻿

High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion. ﻿

Identification of protein expression signatures in clear renal cell carcinoma histological type ﻿

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study ﻿

Long-term progression-free survival (PFS) in patients under sunitinib treatment: A SOG-GU experience ﻿

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

Adenocarcinoma de ciego en paciente con situs inversus totalis.

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples

Bone Turnover Markers and Potential Correlation with Outcomes in Patients with Genitourinary Cancer (Prostate) and Bone Metastasis (Results of Tugamo Study)

Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC)

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

DESCRIPTION OF A SUBPOPULATION OF RENAL PATIENTS WITH LONG-TERM PROGRESSION FREE SURVIVAL (PFS) WITH SUNITINIB: A SOG_GU EXPERIENCE

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment

Evaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion.

Identification of protein expression signatures in clear renal cell carcinoma histological type

Induction chemotherapy with docetaxel (D) and cisplatin (C) followed by concurrent thoracic radiotherapy with biweekly d and C for stage III non-small cell lung cancer (NSCLC) - A galician lung cancer group study

Long-term progression-free survival (PFS) in patients under sunitinib treatment: A SOG-GU experience